Deepak Narayan Parchwani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Deepak Narayan Parchwani has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Ragini Singh
All India Institute of Medical Sciences, Rajkot, India
8 shared publicationsSagar Dholariya
All India Institute of Medical Sciences, Rajkot (Guj) India
6 shared publications- Sagar Dholariya
Department of Biochemistry, All India Institute of Medical Sciences, Rajkot, Gujarat, India
6 shared publications - Amit Sonagra
All India Institute of Medical Sciences
5 shared publications - Ragini Singh
All India Institute of Medical Sciences
5 shared publications - Mehul Kaliya
All India Institute of Medical Sciences
4 shared publications
Latest Publications
- 3 April 2026
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 138 (3) , 332-344
Urinary adiponectin as a non-invasive biomarker of renal impairment in type 2 diabetes mellitus: evidence from a cross-sectional study
1. Diabetic kidney disease (DKD) is a leading cause of chronic kidney disease and end-stage renal disease worldwide, and its burden is particularly high in India, where pooled estimates suggest tha...
- 3 April 2026
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 138 (3) , 332-344
Urinary adiponectin as a non-invasive biomarker of renal impairment in type 2 diabetes mellitus: evidence from a cross-sectional study
1. Diabetic kidney disease (DKD) is a leading cause of chronic kidney disease and end-stage renal disease worldwide, and its burden is particularly high in India, where pooled estimates suggest tha...
- 17 February 2026
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 138 (2) , 162-199
Lipoprotein(a) levels in children and adolescents: a systematic review and meta-analysis of associations with parental cardiovascular disease, familial hypercholesterolemia, and gender differences
Lipoprotein(a) [Lp(a)] is a genetically determined lipoprotein linked to atherosclerotic cardiovascular disease (CVD). Although well studied in adults, its familial determinants in children remain unclear. This systematic review and meta-analysis quantified Lp(a) across pediatric subgroups defined by familial cardiovascular risk, familial hypercholesterolemia (FH), sex, and ethnicity. Following PRISMA 2020 guidelines, fifty-one observational studies were analyzed using random-effects models (Review Manager 5.4.1). Mean differences (MD) with 95% confidence intervals (CI) were calculated. Subgroup, sensitivity, and meta-regression analyses explored heterogeneity. Among children and adolescents with FH, those with a parental history of premature cardiovascular disease (pCVD) had significantly higher Lp(a) concentrations than FH children without parental pCVD (MD = 10.24 mg/dL; 95% CI 3.06-17.43; p = 0.005; I2 = 79%). In otherwise healthy children, parental pCVD was similarly associated with elevated Lp(a) levels (MD = 11.88 mg/dL; p = 0.005). When parental CVD was considered, healthy offspring of affected parents also showed significantly higher Lp(a) concentrations (MD = 7.00 mg/dL; 95% CI 4.45-9.55; p < 0.00001; I2 = 93%). Direct comparison between FH children and healthy controls demonstrated a modest but significant elevation in FH (MD = 1.31 mg/dL; 95% CI 0.19-2.44; p = 0.02; I2 = 74%). Girls exhibited slightly higher Lp(a) levels than boys (MD = -1.48 mg/dL; 95% CI - 2.52 to -0.43; p = 0.006), with minimal pubertal influence. Elevated Lp(a) in children with parental CVD or pCVD reflects a strong heritable pattern from early life. FH was associated with modest but consistent Lp(a) elevation, indicating an independent risk-modifying role rather than a defining feature. Sex-related differences were minimal, whereas ethnic variation was prominent. These findings support targeted Lp(a) assessment in children with familial cardiovascular risk using ancestry-aware reference standards, with consideration of repeat evaluation in early adulthood in higher-risk individuals.
- 17 February 2026
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 138 (2) , 162-199
Lipoprotein(a) levels in children and adolescents: a systematic review and meta-analysis of associations with parental cardiovascular disease, familial hypercholesterolemia, and gender differences
Lipoprotein(a) [Lp(a)] is a genetically determined lipoprotein linked to atherosclerotic cardiovascular disease (CVD). Although well studied in adults, its familial determinants in children remain unclear. This systematic review and meta-analysis quantified Lp(a) across pediatric subgroups defined by familial cardiovascular risk, familial hypercholesterolemia (FH), sex, and ethnicity. Following PRISMA 2020 guidelines, fifty-one observational studies were analyzed using random-effects models (Review Manager 5.4.1). Mean differences (MD) with 95% confidence intervals (CI) were calculated. Subgroup, sensitivity, and meta-regression analyses explored heterogeneity. Among children and adolescents with FH, those with a parental history of premature cardiovascular disease (pCVD) had significantly higher Lp(a) concentrations than FH children without parental pCVD (MD = 10.24 mg/dL; 95% CI 3.06-17.43; p = 0.005; I2 = 79%). In otherwise healthy children, parental pCVD was similarly associated with elevated Lp(a) levels (MD = 11.88 mg/dL; p = 0.005). When parental CVD was considered, healthy offspring of affected parents also showed significantly higher Lp(a) concentrations (MD = 7.00 mg/dL; 95% CI 4.45-9.55; p < 0.00001; I2 = 93%). Direct comparison between FH children and healthy controls demonstrated a modest but significant elevation in FH (MD = 1.31 mg/dL; 95% CI 0.19-2.44; p = 0.02; I2 = 74%). Girls exhibited slightly higher Lp(a) levels than boys (MD = -1.48 mg/dL; 95% CI - 2.52 to -0.43; p = 0.006), with minimal pubertal influence. Elevated Lp(a) in children with parental CVD or pCVD reflects a strong heritable pattern from early life. FH was associated with modest but consistent Lp(a) elevation, indicating an independent risk-modifying role rather than a defining feature. Sex-related differences were minimal, whereas ethnic variation was prominent. These findings support targeted Lp(a) assessment in children with familial cardiovascular risk using ancestry-aware reference standards, with consideration of repeat evaluation in early adulthood in higher-risk individuals.
- 29 December 2025
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 20 (1) , 5-15
Stage-specific association of urinary C-megalin with diabetic kidney disease: a cross-sectional study in type 2 diabetes
This study aimed to evaluate urinary C-megalin in relation to disease staging and diagnostic accuracy in Indian patients with type 2 diabetes mellitus (T2DM). In this cross-sectional study, 325 participants were classified into No-DKD, early-DKD, and late-DKD based on kidney disease improving global outcomes (KDIGO) criteria. Urinary C-megalin was quantified by enzyme-linked immunosorbent assay (ELISA) as absolute and creatinine-normalized values. Group comparisons, correlation analyses, and multinomial logistic regression were performed to assess associations with disease stage. Creatinine-normalized C-megalin excretion was higher in early-DKD compared with No-DKD (median 125.0 vs. 92.0 ng/mg Cr; p = 0.02) and independently associated with early disease [odds ratio (OR) = 1.26, 95% confidence interval (CI): 1.03-1.55; p = 0.02). In late-DKD, absolute C-megalin levels were significantly associated with disease status (OR = 1.23, 95% CI: 1.02-1.48; p = 0.03), while normalized values lost significance. Diagnostic evaluation showed moderate accuracy for detecting early-DKD [area under curve (AUC): 0.69, 95% CI: 0.62-0.76, p = 0.001). Urinary C-megalin demonstrates stage-dependent diagnostic behavior in DKD, suggesting potential as a complementary marker for early tubular injury and advanced disease in high-risk diabetic populations.
- 29 December 2025
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 20 (1) , 5-15
Stage-specific association of urinary C-megalin with diabetic kidney disease: a cross-sectional study in type 2 diabetes
This study aimed to evaluate urinary C-megalin in relation to disease staging and diagnostic accuracy in Indian patients with type 2 diabetes mellitus (T2DM). In this cross-sectional study, 325 participants were classified into No-DKD, early-DKD, and late-DKD based on kidney disease improving global outcomes (KDIGO) criteria. Urinary C-megalin was quantified by enzyme-linked immunosorbent assay (ELISA) as absolute and creatinine-normalized values. Group comparisons, correlation analyses, and multinomial logistic regression were performed to assess associations with disease stage. Creatinine-normalized C-megalin excretion was higher in early-DKD compared with No-DKD (median 125.0 vs. 92.0 ng/mg Cr; p = 0.02) and independently associated with early disease [odds ratio (OR) = 1.26, 95% confidence interval (CI): 1.03-1.55; p = 0.02). In late-DKD, absolute C-megalin levels were significantly associated with disease status (OR = 1.23, 95% CI: 1.02-1.48; p = 0.03), while normalized values lost significance. Diagnostic evaluation showed moderate accuracy for detecting early-DKD [area under curve (AUC): 0.69, 95% CI: 0.62-0.76, p = 0.001). Urinary C-megalin demonstrates stage-dependent diagnostic behavior in DKD, suggesting potential as a complementary marker for early tubular injury and advanced disease in high-risk diabetic populations.
- 22 October 2025
- Published by Springer Nature in Indian Journal of Clinical Biochemistry
- p. 1-32
Oxidative-Inflammo Mechanism of Heavy Metal Toxicity
- 22 October 2025
- Published by Springer Nature in Indian Journal of Clinical Biochemistry
- p. 1-32
Oxidative-Inflammo Mechanism of Heavy Metal Toxicity
- Open Access
- 1 October 2025
- Vol. 36 (3) , 284-297
Role of Inflammatory and Oxidative Stress Biomarkers with Albuminuria: A Cross Sectional Analysis in Type 2 Diabetes Mellitus Patients
Diabetic nephropathy (DN) is a prevalent and severe complication of type 2 diabetes mellitus (T2DM), contributing to kidney disease and cardiovascular risks. Oxidative stress and inflammation play crucial roles in DN pathogenesis. This study investigates the association of inflammatory cytokines, oxidative stress markers, and cortisol with albuminuria in T2DM patients. A cross-sectional study was conducted on 150 T2DM patients categorized into normoalbuminuria, microalbuminuria, and macroalbuminuria groups. Blood samples were analyzed for total antioxidant capacity (T-AOC), pro-inflammatory cytokines (TNF-α, IL-1, IL-6, IL-8), high-sensitivity C-reactive protein (hsCRP), and cortisol levels. Statistical analyses included ANOVA and logistic regression. T2DM patients with albuminuria exhibited significantly lower T-AOC (P=0.027) and elevated TNF-α (P=0.006), IL-1 (P<0.001), IL-6 (P<0.001), IL-8 (P<0.001), hsCRP (P<0.001), and cortisol (P<0.001). High tertiles of TNF-α, IL-6, and hsCRP were strongly associated with increased albuminuria risk, particularly in overweight and hypertensive patients. The findings highlight the interplay of oxidative stress, inflammation, and metabolic dysregulation in DN progression. Elevated inflammatory markers and cortisol levels correlate with albuminuria severity, emphasizing their potential as biomarkers for early DN detection. Targeting inflammatory pathways may offer therapeutic strategies to mitigate DN progression in T2DM patients.
- 1 October 2025
- Vol. 36 (3) , 284-297
Open AccessRole of Inflammatory and Oxidative Stress Biomarkers with Albuminuria: A Cross Sectional Analysis in Type 2 Diabetes Mellitus Patients
Diabetic nephropathy (DN) is a prevalent and severe complication of type 2 diabetes mellitus (T2DM), contributing to kidney disease and cardiovascular risks. Oxidative stress and inflammation play crucial roles in DN pathogenesis. This study investigates the association of inflammatory cytokines, oxidative stress markers, and cortisol with albuminuria in T2DM patients. A cross-sectional study was conducted on 150 T2DM patients categorized into normoalbuminuria, microalbuminuria, and macroalbuminuria groups. Blood samples were analyzed for total antioxidant capacity (T-AOC), pro-inflammatory cytokines (TNF-α, IL-1, IL-6, IL-8), high-sensitivity C-reactive protein (hsCRP), and cortisol levels. Statistical analyses included ANOVA and logistic regression. T2DM patients with albuminuria exhibited significantly lower T-AOC (P=0.027) and elevated TNF-α (P=0.006), IL-1 (P<0.001), IL-6 (P<0.001), IL-8 (P<0.001), hsCRP (P<0.001), and cortisol (P<0.001). High tertiles of TNF-α, IL-6, and hsCRP were strongly associated with increased albuminuria risk, particularly in overweight and hypertensive patients. The findings highlight the interplay of oxidative stress, inflammation, and metabolic dysregulation in DN progression. Elevated inflammatory markers and cortisol levels correlate with albuminuria severity, emphasizing their potential as biomarkers for early DN detection. Targeting inflammatory pathways may offer therapeutic strategies to mitigate DN progression in T2DM patients.
- Open Access
- 20 September 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Methodology
- Vol. 15 (3) , 102709
Biological and translational attributes of mitochondrial DNA copy number: Laboratory perspective to clinical relevance
The mitochondrial DNA copy number (mtDNAcn) plays a vital role in cellular energy metabolism and mitochondrial health. As mitochondria are responsible for adenosine triphosphate production through oxidative phosphorylation, maintaining an appropriate mtDNAcn level is vital for the overall cellular function. Alterations in mtDNAcn have been linked to various diseases, including neurodegenerative disorders, metabolic conditions, and cancers, making it an important biomarker for understanding the disease pathogenesis. The accurate estimation of mtDNAcn is essential for clinical applications. Quantitative polymerase chain reaction and next-generation sequencing are commonly employed techniques with distinct advantages and limitations. Clinically, mtDNAcn serves as a valuable indicator for early diagnosis, disease progression, and treatment response. For instance, in oncology, elevated mtDNAcn levels in blood samples are associated with tumor aggressiveness and can aid in monitoring treatment efficacy. In neurodegenerative diseases such as Alzheimer’s and Parkinson’s, altered mtDNAcn patterns provide insights into disease mechanisms and progression. Understanding and estimating mtDNAcn are critical for advancing diagnostic and therapeutic strategies in various medical fields. As research continues to uncover the implications of mtDNAcn alterations, its potential as a clinical biomarker is likely to expand, thereby enhancing our ability to diagnose and manage complex diseases.
- 20 September 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Methodology
- Vol. 15 (3) , 102709
Open AccessBiological and translational attributes of mitochondrial DNA copy number: Laboratory perspective to clinical relevance
The mitochondrial DNA copy number (mtDNAcn) plays a vital role in cellular energy metabolism and mitochondrial health. As mitochondria are responsible for adenosine triphosphate production through oxidative phosphorylation, maintaining an appropriate mtDNAcn level is vital for the overall cellular function. Alterations in mtDNAcn have been linked to various diseases, including neurodegenerative disorders, metabolic conditions, and cancers, making it an important biomarker for understanding the disease pathogenesis. The accurate estimation of mtDNAcn is essential for clinical applications. Quantitative polymerase chain reaction and next-generation sequencing are commonly employed techniques with distinct advantages and limitations. Clinically, mtDNAcn serves as a valuable indicator for early diagnosis, disease progression, and treatment response. For instance, in oncology, elevated mtDNAcn levels in blood samples are associated with tumor aggressiveness and can aid in monitoring treatment efficacy. In neurodegenerative diseases such as Alzheimer’s and Parkinson’s, altered mtDNAcn patterns provide insights into disease mechanisms and progression. Understanding and estimating mtDNAcn are critical for advancing diagnostic and therapeutic strategies in various medical fields. As research continues to uncover the implications of mtDNAcn alterations, its potential as a clinical biomarker is likely to expand, thereby enhancing our ability to diagnose and manage complex diseases.
- 13 November 2024
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 40 (12) , 2025-2055
Unveiling the utility of artificial intelligence for prediction, diagnosis, and progression of diabetic kidney disease: an evidence-based systematic review and meta-analysis
The purpose of this study was to conduct a systematic investigation of the potential of artificial intelligence (AI) models in the prediction, detection of diagnostic biomarkers, and progression of diabetic kidney disease (DKD). In addition, we compared the performance of non-logistic regression (LR) machine learning (ML) models to conventional LR prediction models. Until January 30, 2024, a comprehensive literature review was conducted by investigating databases such as Medline (via PubMed) and Cochrane. Research that is inclusive of AI or ML models for the prediction, diagnosis, and progression of DKD was incorporated. The area under the Receiver Operating Characteristic Curve (AUROC) served as the principal outcome metric for assessing model performance. A meta-analysis was performed utilizing MedCalc statistical software to calculate pooled AUROC and assess the performance differences between LR and non-LR models. A total of 57 studies were included in the meta-analysis. The pooled AUROC of AI or ML model was 0.84 (95% CI = 0.81-0.86, p < 0.0001) for analyzing prediction of DKD, 0.88 (95%CI = 0.84-0.92, p < 0.0001) for detecting diagnostic biomarkers, and 0.80 (95% CI = 0.77-0.82, p < 0.0001) for analyzing progression of DKD. The pooled AUROC of LR and non-LR ML models exhibited no significant differences across all categories (p > 0.05), except for the random forest (RF) model, which displayed a statistically significant increase in predictive accuracy compared to LR for DKD occurrence (p < 0.04). ML models showed solid DKD prediction effectiveness, with pooled AUROC values over 0.8, suggesting good performance. These data demonstrated that non-LR and LR models perform similarly in overall CKD management, but the RF model outperforms the LR model, particularly in predicting the occurrence of DKD. These findings highlight the promise of AI technologies for better DKD management. To improve model reliability, future study should include extended follow-up periods as well as external validation.
- 13 November 2024
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 40 (12) , 2025-2055
Unveiling the utility of artificial intelligence for prediction, diagnosis, and progression of diabetic kidney disease: an evidence-based systematic review and meta-analysis
The purpose of this study was to conduct a systematic investigation of the potential of artificial intelligence (AI) models in the prediction, detection of diagnostic biomarkers, and progression of diabetic kidney disease (DKD). In addition, we compared the performance of non-logistic regression (LR) machine learning (ML) models to conventional LR prediction models. Until January 30, 2024, a comprehensive literature review was conducted by investigating databases such as Medline (via PubMed) and Cochrane. Research that is inclusive of AI or ML models for the prediction, diagnosis, and progression of DKD was incorporated. The area under the Receiver Operating Characteristic Curve (AUROC) served as the principal outcome metric for assessing model performance. A meta-analysis was performed utilizing MedCalc statistical software to calculate pooled AUROC and assess the performance differences between LR and non-LR models. A total of 57 studies were included in the meta-analysis. The pooled AUROC of AI or ML model was 0.84 (95% CI = 0.81-0.86, p < 0.0001) for analyzing prediction of DKD, 0.88 (95%CI = 0.84-0.92, p < 0.0001) for detecting diagnostic biomarkers, and 0.80 (95% CI = 0.77-0.82, p < 0.0001) for analyzing progression of DKD. The pooled AUROC of LR and non-LR ML models exhibited no significant differences across all categories (p > 0.05), except for the random forest (RF) model, which displayed a statistically significant increase in predictive accuracy compared to LR for DKD occurrence (p < 0.04). ML models showed solid DKD prediction effectiveness, with pooled AUROC values over 0.8, suggesting good performance. These data demonstrated that non-LR and LR models perform similarly in overall CKD management, but the RF model outperforms the LR model, particularly in predicting the occurrence of DKD. These findings highlight the promise of AI technologies for better DKD management. To improve model reliability, future study should include extended follow-up periods as well as external validation.
- 10 November 2023
- Published by Springer Nature in Indian Journal of Clinical Biochemistry
- Vol. 39 (3) , 438-441
Detection of HbD Punjab Trait in Saurashtra Region of Gujarat by HPLC Method
The HbD Punjab trait is a less common hemoglobin variant in the Saurashtra region of Gujarat. This patient presented to the General Medicine and Biochemistry Department at All India Institute of Medical Sciences, Rajkot, Hospital, for the HbA1c analysis by high-performance liquid chromatography (HPLC). The patient was 52 years old, a known case of type 2 diabetes mellitus and hypertension, and presented with complaints of generalized malaise and fatigability for the previous ten to twelve months. On physical examination, there was no evidence of pallor, lymphadenopathy, splenomegaly, or hepatomegaly. Peripheral blood smear revealed normocytic normochromic RBC, and platelets were adequate and normal in morphology. The HPLC analysis revealed heterozygous for hemoglobin D (HbD Punjab trait), and false high HbA1c corresponds to fasting plasma glucose (FPG) levels due to abnormal separation. However, genetic counseling is highly recommended to detect any potential reproductive risk factors.
- 10 November 2023
- Published by Springer Nature in Indian Journal of Clinical Biochemistry
- Vol. 39 (3) , 438-441
Detection of HbD Punjab Trait in Saurashtra Region of Gujarat by HPLC Method
The HbD Punjab trait is a less common hemoglobin variant in the Saurashtra region of Gujarat. This patient presented to the General Medicine and Biochemistry Department at All India Institute of Medical Sciences, Rajkot, Hospital, for the HbA1c analysis by high-performance liquid chromatography (HPLC). The patient was 52 years old, a known case of type 2 diabetes mellitus and hypertension, and presented with complaints of generalized malaise and fatigability for the previous ten to twelve months. On physical examination, there was no evidence of pallor, lymphadenopathy, splenomegaly, or hepatomegaly. Peripheral blood smear revealed normocytic normochromic RBC, and platelets were adequate and normal in morphology. The HPLC analysis revealed heterozygous for hemoglobin D (HbD Punjab trait), and false high HbA1c corresponds to fasting plasma glucose (FPG) levels due to abnormal separation. However, genetic counseling is highly recommended to detect any potential reproductive risk factors.
- 20 October 2023
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 24 (18) , 2187-2198
Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis
This study assessed the clinical safety and efficacy of bexagliflozin, a sodium-glucose cotransporter 2(SGLT2) inhibitor, in managing glycemia among patients with type 2 diabetes mellitus (T2DM). We examined RCTs with T2DM comparing the clinical effectiveness and safety of 20 mg once daily oral dose of bexagliflozin with placebo for managing glycemia till 28 May 2023, published on databases like ClinicalTrials.gov, PubMed, Embase, and Cochrane Library. Furthermore, reduction of body weight and systolic blood pressure (SBP) and the percentage of individuals who achieved glycated hemoglobin (HbA1c) of < 7% from baseline were also evaluated. The Review Manager 5 was utilized to investigate the retrieved data. We involved eight RCTs. Bexagliflozin was significantly superior in reducing HbA1c[least squares mean difference(LSMD) = -0.45,95% confidence interval (CI =-0.55 to -0.34,p < 0.00001], fasting plasma sugar(FPG)[LSMD= -1.37, 95%CI =-1.73 to -1.00, p < 0.00001], body weight (LSMD= -1.77, 95%CI =-2.44 to-1.10, p < 0.00001), and SBP(LSMD= -4.11,95%CI = -6.18 to -2.03,p = 0.0001) in comparison to placebo. The safety outcomes of bexagliflozin were consistent with the placebo arm. This study concluded that bexagliflozin seems to be a promising oral anti-diabetic drug for enhancing glycemic management in adult patients with T2DM.
- 20 October 2023
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 24 (18) , 2187-2198
Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis
This study assessed the clinical safety and efficacy of bexagliflozin, a sodium-glucose cotransporter 2(SGLT2) inhibitor, in managing glycemia among patients with type 2 diabetes mellitus (T2DM). We examined RCTs with T2DM comparing the clinical effectiveness and safety of 20 mg once daily oral dose of bexagliflozin with placebo for managing glycemia till 28 May 2023, published on databases like ClinicalTrials.gov, PubMed, Embase, and Cochrane Library. Furthermore, reduction of body weight and systolic blood pressure (SBP) and the percentage of individuals who achieved glycated hemoglobin (HbA1c) of < 7% from baseline were also evaluated. The Review Manager 5 was utilized to investigate the retrieved data. We involved eight RCTs. Bexagliflozin was significantly superior in reducing HbA1c[least squares mean difference(LSMD) = -0.45,95% confidence interval (CI =-0.55 to -0.34,p < 0.00001], fasting plasma sugar(FPG)[LSMD= -1.37, 95%CI =-1.73 to -1.00, p < 0.00001], body weight (LSMD= -1.77, 95%CI =-2.44 to-1.10, p < 0.00001), and SBP(LSMD= -4.11,95%CI = -6.18 to -2.03,p = 0.0001) in comparison to placebo. The safety outcomes of bexagliflozin were consistent with the placebo arm. This study concluded that bexagliflozin seems to be a promising oral anti-diabetic drug for enhancing glycemic management in adult patients with T2DM.
- 11 November 2022
- Published by Springer Nature in Indian Journal of Clinical Biochemistry
- Vol. 39 (2) , 264-270
Evaluation of Laboratory Performance in Consideration with Pre analytical and Post analytical Quality Indicators
Implementation of Quality indicators (QIs) plays an imperative role in improving the total testing process, as it provides a quantitative basis for evaluating the laboratory performance. Besides monitoring of analytical quality specifications, several lines of experimental and clinical evidence have alluded a pivotal role of extra-analytical phases in improving the quality of laboratory services and therefore a relevance of pre- and post-analytical steps have been speculated on the overall quality in the total testing process and consequently on clinical decision-making. This was a retrospective study designed to evaluate and review different extra-analytical quality indicators in NABL accredited clinical biochemistry laboratory at BJ Medical College and Civil Hospital, Ahmedabad, Gujarat in an endeavour to ameliorate the performance of the laboratory. All Clinical Chemistry Laboratory test requests with their respective samples from January 2018 to December 2021 were included in the study. A total of 1,439,011samples were processed, and were evaluated for seven QIs [(% of number of suitable samples not received; QI-8), (% of number of samples received in inappropriate container; QI-9), (% of number of samples hemolysed; QI-10), (% of number of samples with inadequate sample volume; QI 12) (% of number of samples received mismatched; QI 15), (% of number of samples reported after turnaround time; QI 21) and (% of number of samples with critical values informed; QI 22)] based on defined criteria of Quality Specification given by International Federation of Clinical Chemistry. Total number of preanalytical errors was 53,669 (3.72%). Among the preanalytical errors, inadequate sample volume (2.37% of total samples; 63.49% of total pre-analytical errors) was the most common anomaly followed by Not received samples (24.18%) hemolysis (8.26%) mismatched (3.91%) and 0.14% samples were received in Inappropriate container; manifesting that the error frequency was unacceptable for QI 21 and QI 8, acceptable for QI 10, minimally acceptable for QI 15 and optimum for QI QI 9. Furthermore, there was year-wise progressive decline in error rate of inadequate sample volume, hemolysed sample received and mismatched samples. Total number of post analytical errors were 19,002 (1.32%). TAT outlier and critical values communicated were the two QIs evaluated for this phase and results of both QI were within acceptable limits. Quality indicators serve as a tool to monitor process performance and consequently derived error rates warrant active intervention to improve the laboratory services and patient health care. Dissemination of certified documents, regular staff training and evaluation needs to be conducted.
- 11 November 2022
- Published by Springer Nature in Indian Journal of Clinical Biochemistry
- Vol. 39 (2) , 264-270
Evaluation of Laboratory Performance in Consideration with Pre analytical and Post analytical Quality Indicators
Implementation of Quality indicators (QIs) plays an imperative role in improving the total testing process, as it provides a quantitative basis for evaluating the laboratory performance. Besides monitoring of analytical quality specifications, several lines of experimental and clinical evidence have alluded a pivotal role of extra-analytical phases in improving the quality of laboratory services and therefore a relevance of pre- and post-analytical steps have been speculated on the overall quality in the total testing process and consequently on clinical decision-making. This was a retrospective study designed to evaluate and review different extra-analytical quality indicators in NABL accredited clinical biochemistry laboratory at BJ Medical College and Civil Hospital, Ahmedabad, Gujarat in an endeavour to ameliorate the performance of the laboratory. All Clinical Chemistry Laboratory test requests with their respective samples from January 2018 to December 2021 were included in the study. A total of 1,439,011samples were processed, and were evaluated for seven QIs [(% of number of suitable samples not received; QI-8), (% of number of samples received in inappropriate container; QI-9), (% of number of samples hemolysed; QI-10), (% of number of samples with inadequate sample volume; QI 12) (% of number of samples received mismatched; QI 15), (% of number of samples reported after turnaround time; QI 21) and (% of number of samples with critical values informed; QI 22)] based on defined criteria of Quality Specification given by International Federation of Clinical Chemistry. Total number of preanalytical errors was 53,669 (3.72%). Among the preanalytical errors, inadequate sample volume (2.37% of total samples; 63.49% of total pre-analytical errors) was the most common anomaly followed by Not received samples (24.18%) hemolysis (8.26%) mismatched (3.91%) and 0.14% samples were received in Inappropriate container; manifesting that the error frequency was unacceptable for QI 21 and QI 8, acceptable for QI 10, minimally acceptable for QI 15 and optimum for QI QI 9. Furthermore, there was year-wise progressive decline in error rate of inadequate sample volume, hemolysed sample received and mismatched samples. Total number of post analytical errors were 19,002 (1.32%). TAT outlier and critical values communicated were the two QIs evaluated for this phase and results of both QI were within acceptable limits. Quality indicators serve as a tool to monitor process performance and consequently derived error rates warrant active intervention to improve the laboratory services and patient health care. Dissemination of certified documents, regular staff training and evaluation needs to be conducted.